MedTrace Logo

A Study of HS-20110 in Participants With Advanced Solid Tumors

NCT06892379 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 475

Last updated 2026-04-20

No results posted yet for this study

Summary

This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors

Conditions

Interventions

DRUG

HS-20110 (Phase Ia：Dose escalation )

HS-20110 for IV infusion of various dose strengths administered in 21 day dosing cycles

DRUG

HS-20110 (Phase Ib:Dose expansion )

The recommended dose from the dose-escalation stage and other potential doses will be further explored

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Hansoh BioMedical R&D Company

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-26
Primary Completion
2026-12-31
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06892379 on ClinicalTrials.gov